EBMT 2021 | Real-world data on CAR-T therapy for B-ALL
Stephan Grupp, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, outlines recent advances in the use of chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of lymphoid malignancies, highlighting real-world data. Dr Grupp discusses results from the Phase II ELIANA study (NCT02435849) investigating the efficacy and safety of CTL019 in pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
Disclosures
Dr Stephan Grupp, MD, PhD, has received research support from Novartis, Servier, Vertex and Kite; and has participated in study steering committees, consulting, or scientific advisory boards with Novartis, Allogene, Adaptimmune, TCR2, Cabaletta, Juno, CBMG, GlaxoSmithKline, Cellectis, Johnson & Johnson/Janssen, CRISPR/Vertex, Roche, Humanigen and Jazz.
